How Does 23andMe Company Segment and Target Its Market?

23andMe targets consumers aged 35-65 with mid-to-upper incomes and higher education who buy health reports and subscriptions; these users drive recurring revenue and higher lifetime value under the company's market segmentation 23andMe approach.

Ancestry-focused buyers seek identity and lineage, produce high unit volumes for direct-to-consumer genetics marketing, and fuel customer acquisition and viral referrals despite lower per-user revenue versus health products.

23andMe operates a dual B2C and B2B model: consumer genetics kits plus subscription health services, and partnerships selling access to a consented database of over 14 million genotyped individuals to pharma clients - a clear 23andMe B2C vs B2B targeting approach.

Health-motivated subscribers are most strategic by revenue per user and retention; they support recurring subscription income and enable higher-margin upsells and targeted advertising, making them the priority in 23andMe marketing strategy and customer segmentation genetic testing efforts.

The U.S. captures the largest share of 23andMe market segmentation 23andMe revenue and users: in 2025 the U.S. accounted for roughly ~70% of direct-to-consumer kit sales, driven by affluent, longevity-focused buyers and biohackers who pay premium prices for health reports and data-driven wellness insights.

Other strong pockets include the U.K., Canada, and Australia where cultural alignment and English-language marketing lower acquisition friction; 23andMe target market tactics favor ancestry purchases among older adults and health-product upsells to Gen X and younger millennials.

23andMe is strongest in U.S. B2C revenue and B2B collaborations: by 2025 partnerships and research collaborations-anchored in pharma hubs-contributed materially to non-kit revenue, with clinical and drug-discovery agreements concentrated around Boston, San Francisco, and Basel.

In 2025 the fastest growth came from B2B licensing and research partnerships: pharma-focused demand in Basel, Boston, and San Francisco rose as drug developers paid for access to aggregated genotype-phenotype signals, increasing B2B revenue share and validating 23andMe B2C vs B2B targeting approaches; see the Go-to-Market Strategy of 23andMe Company for context: Go-to-Market Strategy of 23andMe Company

Core customers-ancestry seekers and health-curious consumers-delivered one-time kit revenue and large genetic datasets, showing clear market segmentation 23andMe achieved. That fit powered a genetic moat but did not translate to recurring LTV needed for capital-intensive biopharma.

Attempts to expand into telehealth, memberships, and B2B licensing (notably an Almirall pact up to $86.5 million) reflect a shift from B2C toward healthcare and biopharma targeting. Those moves aimed to monetize data via genetic testing market targeting but proved insufficient for R&D scale.

Low repeat purchase rates for DNA kits meant shallow account depth and poor subscription stickiness; membership pilots failed to offset churn. Retention metrics favored one-time B2C transactions over recurring revenue-key for sustainable LTV.

By March 23, 2025 23andMe filed Chapter 11 and sold substantially all assets to TTAM Research Institute for $305 million (closed July 14, 2025), proving the customer mix could not underwrite biopharma ambitions. The dataset and targeting were strong-see Operating Model of 23andMe Company-but LTV, retention, and capital mismatch doomed the pivot from ancestry and health kits to drug development.